Retatrutide
$320.00Retatrutide is the next-generation triple agonist (GLP-1 / GIP / Glucagon receptor agonist) showing remarkable results in metabolic regulation, energy expenditure, and fat reduction.
Why Choose Retatrutide?
State-of-the-art triple hormone pathway targeting appetite suppression, insulin sensitivity, and increased metabolic calorie burning simultaneously.
How to Use
Administer once weekly via subcutaneous injection. Follow the recommended dosage protocol provided with your order.
Safety Information
For adult research and medically guided protocols. Ensure appropriate hydration and follow recommended titration schedules strictly.
Potential Side Effects
Transient nausea, appetite changes, mild gastrointestinal adjustment, and initial fatigue as metabolism adapts.
Product Facts
| Generic Name | Retatrutide |
| Brand Name | Retatrutide |
| Type of Medication | Triple GIP / GLP-1 / Glucagon Receptor Agonist |
| FDA Approval Date | January 1, 2024 |
| Indications | Targeted for advanced metabolic enhancement, intensive weight reduction, and liver fat elimination. |
| Dosage Forms | Prefilled subcutaneous pen / vial solution |
| Administration | Once weekly subcutaneous injection |
| Special Precautions | Use under professional guidance. Ensure strict titration adherence to prevent gastrointestinal discomfort. |
| Drug Interactions | Delayed gastric motility may alter oral drug absorption profiles. |
| Use in Specific Populations | Safety and efficacy in pediatric and pregnant populations subject to medical oversight. |
| Prescription | Prescription Required |
| Manufacturer | Eli Lilly and Company |
How to Buy
Select your desired concentration, add to cart, and order with full confidentiality and expedited cold-chain shipping.